Determination of the methylation status of MGMT in different regions within glioblastoma multiforme

Journal of Neuro-Oncology

Volumn 102, Issue 2, 2011, Pages 255-260

  Hamilton, Mark G ^c   Roldán, Gloria ^a   Magliocco, Anthony ^a   McIntyre, John B ^a   Parney, Ian ^b   Easaw, Jacob C ^a  

^a TOM BAKER CANCER CENTRE   (Canada)

^b MAYO CLINIC   (United States)

^c NONE

Author keywords

Brain tumor; GBM; Glioblastoma; Heterogeneity; Homogeneity; Methylation; MGMT

Indexed keywords

PARAFFIN;

ADULT; AGED; ARTICLE; BRAIN BIOPSY; CLINICAL ARTICLE; CONTROLLED STUDY; CRYOPRESERVATION; DNA METHYLATION; FEMALE; GENE; GLIOBLASTOMA; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MGMT GENE; MOLECULAR PATHOLOGY; POLYMERASE CHAIN REACTION; PROMOTER REGION; TISSUE FIXATION;

ADULT; AGED; BRAIN NEOPLASMS; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; DNA, NEOPLASM; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMOTER REGIONS, GENETIC; TUMOR SUPPRESSOR PROTEINS;

EID: 79953677481     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-010-0307-5     Document Type: Article

References (21)

1. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996 (Pubitemid 40349501)
2. van Rijn J, Heimans JJ, van den Berg J, van der Valk P, Slotman BJ (2000) Survival of human glioma cells treated with various combination of temozolomide and X-rays. Int J Radiat Oncol Biol Phys 47:779-784
3. Wedge SR, Porteous JK, Glaser MG, Marcus K, Newlands ES (1997) In vitro evaluation of temozolomide combined with X-irradiation. Anticancer Drugs 8:92-97
4. Wick W, Wick A, Schulz JB, Dichgans J, Rodemann HP, Weller M (2002) Prevention of irradiation-induced glioma cell invasion by temozolomide involves caspase 3 activity and cleavage of focal adhesion kinase. Cancer Res 62:1915-1919 (Pubitemid 34408522)
5. Hegi ME, Diserens AC, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997-1003 (Pubitemid 40349502)
6. Liu L, Markowitz S, Gerson SL (1996) Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea. Cancer Res 56:5375-5379 (Pubitemid 27011367)
7. Ochs K, Kaina B (2000) Apoptosis induced by DNA damage O6-methylguanine is bcl-2 and caspase-9/3 regulated and Fas/caspase-8 independent. Cancer Res 60:5815-5824
8. Esteller M, Garcia-Foncillas J, Andion E et al (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343:1350-1354
9. Hegi ME, Diserens AC, Godard S et al (2004) Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 10:1871-1874 (Pubitemid 38375541)
10. Juillerat-Jeanneret L, Bernasconi CC, Bricod C et al (2008) Heterogeneity of human glioblastoma: Glutathione-S-transferase and methylguanine- methyltransferase. Cancer Invest 26:597-609 (Pubitemid 351918586)
11. Parkinson JF, Wheeler HR, Clarkson A et al (2008) Variation of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma. J Neurooncol 87:71-78
12. Srinivasan M, Sedmak D, Jewell S (2002) Effect of fixatives and tissue processing on the content and integrity of nucleic acids. Am J Pathol 161:1961-1971 (Pubitemid 35434840)
13. Talaulikar D, Gray JX, Shadbolt B, McNiven M, Dahlstrom JE (2008) A comparative study of the quality of DNA obtained from fresh frozen and formalin-fixed decalcified paraffin-embedded bone marrow trephine biopsy specimens using two different methods. J Clin Pathol 61:119-123 (Pubitemid 351158237)
14. Cao VT, Jung TY, Jung S et al (2009) The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastomas. Neurosurgery 65:866-875
15. Grasbon-Frodl EM, Kreth FW, Ruiter M et al (2007) Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas. Int J Cancer 121:2458-2464 (Pubitemid 350022415)
16. Nakagawa T, Ido K, Sakuma T, Takeuchi H, Sato K, Kubota T (2009) Prognostic significance of the immunohistochemical expression of O(6)-methylguanine-DNA methyltransferase, P-glycoprotein, and multidrug resistance protein-1 in glioblastomas. Neuropathology 29:379-388
17. Yachi K, Watanabe T, Ohta T et al (2008) Relevance of MSP assay for the detection of MGMT promoter hypermethylation in glioblastomas. Int J Oncol 33:469-475
18. Preusser M, Elezi L, Hainfellner JA (2008) Reliability and reproducibility of PCR-based testing of O6-methylguanine-DNA methyltransferase gene (MGMT) promoter methylation status in formalin-fixed and paraffin-embedded neurosurgical biopsy specimens. Clin Neuropathol 27:388-390
19. Wller M, Stupp R, Reifenberger G et al (2010) MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol 6:39-51
20. Cilengitide for subjects with newly diagnosed glioblastoma multiforme and methylated mgmt gene promoter - a multicenter, open-label, controlled phase III study, testing cilengitide in combination with standard treatment (temozolomide with concomitant radiation therapy, followed by temozolomide maintenance therapy) versus standard treatment alone. http://www.clinicaltrials.gov/ct2/ show/NCT00689221. Accessed 16 Feb 2010
21. Cilengitide in subjects with newly diagnosed glioblastoma multiforme and unmethylated mgmt gene promoter - a multicenter, open-label phase ii study, investigating two cilengitide regimens in combination with standard treatment (temozolomide with concomitant radiation therapy, followed by temozolomide maintenance therapy). http://www.clinicaltrials.gov/ct2/show/NCT00813943. Accessed 16 Feb 2010